Uncategorized
Clearside launches phase 2 clinical trial for triamcinolone acetonide
Clearside Biomedical has begun enrollment for a phase 2 clinical trial to evaluate triamcinolone acetonide in the treatment of macular edema associated with retinal vein occlusion, according to a press release.Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, is administered via suprachoroidal injection with the company’s micro-injector.